Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

On November 12, 2026 Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, reported a corporate update and announced third quarter 2026 financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. "FORTIFY continues to enroll ahead of schedule, with a number of European sites onboarded during the quarter. In addition, we continue to explore the potential of our proprietary drug delivery platform with cross-species preclinical data demonstrating successful selective delivery of siRNA payloads to extrahepatic tissues. With emerging data continuing to inform our next steps, potential therapeutic applications and paths forward, we will provide a comprehensive overview of the program in the coming months."

Oncology Program
PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. Pliant is currently conducting FORTIFY, a Phase 1a/1b open-label, dose-escalation and indication expansion trial (NCT06270706), to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors.

•Strong enrollment continues in FORTIFY, a Phase 1b indication expansion trial. FORTIFY will enroll up to 102 patients across three cohorts including non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC) and tumors with high tumor mutational burden. Patients are treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab is added as combination therapy. Enrollment remains strong, progressing ahead of schedule with active sites in the United States and Spain with additional countries onboarding in the next several months. Interim data is expected in 2027.

•Presentations at Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) highlight PLN-101095 Phase 1 biomarker data and mechanism of action.
◦Researchers from Pliant presented new biomarker data from the Phase 1 trial showing that early induction of immune activation biomarkers during PLN-101095 monotherapy was associated with subsequent clinical response following pembrolizumab initiation. These findings support the hypothesis that TGF-β pathway inhibition promotes immune activation, T-cell recruitment into the tumor microenvironment, and enhanced cytotoxic effector function.
◦Researchers from the National Cancer Institute presented data demonstrating that the blockade of integrins αvβ8 and αvβ1 in combination with anti-PD-1 reduced TGF-β signaling leading to modulation of fibroblastic cell populations in the tumor microenvironment and increased infiltration and activation of cytotoxic CD8+ T cells. This resulted in an improvement in anti-tumor activity and survival.

Selective, Targeted, Integrin-mediated Delivery Platform
Utilizing our fully annotated library of 15,000+ integrin binding molecules, as well as our biological knowledge of cell-specific integrin receptor expression, Pliant has created a selective, targeted integrin-mediated delivery platform for cell- and tissue-selective extrahepatic delivery of drug payloads, including RNAi. The platform has broad applicability across multiple disease areas utilizing a variety of drug payloads.

•Tissue Specificity, Potency and Durability – Pliant has initiated multiple RNAi delivery programs targeting specific tissues through unique integrin expression profiles. The most advanced compounds to date selectively target skeletal and skeletal/cardiac muscle, respectively. In non-human primate studies, we have observed >75% target gene knockdown at eight weeks while avoiding liver and other non-targeted tissues.

•Plug-and-Play Compatibility – Pliant’s integrin-directed small molecule delivery compounds can be loaded with RNAi payloads directed at any gene of interest. This allows a single compound to serve as the basis for rapid development of tissue-specific therapies to a broad array of indications. Additionally, while initial efforts are directed at RNAi, the platform is potentially capable of delivering a variety of therapeutic payloads.

•Initial Indications – Based on early findings showing the successful selective delivery of Pliant’s skeletal and cardiac muscle compounds, the Company plans to accelerate development with initial therapeutic programs focused in areas of high unmet need including neuromuscular diseases and rare cardiomyopathies where gene suppression modalities show promise.

Pliant plans to share additional details regarding muscle and cardiac, as well as other RNAi programs, including detailed preclinical data and specific indication and gene targets for development over the coming months.

A presentation on the platform, including preclinical data, titled "Pliant’s Selective Targeted Integrin-Mediated Drug Delivery Platform" can be found in the "Investors & Media" section of Pliant’s website at www.PliantRx.com.

Corporate Highlights
•Appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben is a leader in targeted immuno-oncology drug development and brings three decades of academic and biopharmaceutical oncology expertise. Most recently, Dr. Raben served as Chief Medical Officer at Bicara Therapeutics.
•Appointment of Craig Blanchette, Ph.D., as Senior Vice President, Research (RNAi). Dr. Blanchette is a recognized leader in RNAi drug discovery with a track record of advancing novel delivery platforms and therapeutics. Dr. Blanchette brings more than two decades of drug discovery and development expertise, having most recently served as Chief Scientific Officer at Switch Therapeutics.

Third Quarter 2026 Financial Results
•Research and development expenses were $17.9 million in the current and prior-year quarter. Expenses remained consistent as increased spending on PLN-101095 development in the current period was offset by decreased costs resulting from the termination of bexotegrast development in IPF and reduced personnel- related expenses, including stock based compensation, driven by decreased headcount compared to prior year.
•General and administrative expenses were $7.8 million, as compared to $10.3 million for the prior-year quarter. The decrease was primarily due to personnel-related expenses, including stock-based compensation, driven by decreased headcount compared to prior year.
•Net loss was $24.4 million as compared to $26.3 million for the prior-year quarter. The decrease was primarily due to lower operating expenses following the termination of bexotegrast development in IPF in 2025 and decreased personnel-related expenses, including stock-based compensation, driven by reduced headcount compared to prior year.
•As of September 30, 2026, the Company had cash, cash equivalents and short-term investments of $142.6 million which the Company expects to be sufficient to fund operations to mid-2028.

(Press release, Pliant Therapeutics, NOV 12, 2026, View Source [SID1234674682])

Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress

On November 12, 2026 Aktis Oncology, Inc. (NASDAQ:AKTS) ("Aktis" or the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, reported financial results for the third quarter ended September 30, 2026, and provided a business update, including progress with the Company’s two clinical-stage programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision," said Matthew Roden, Ph.D., President and Chief Executive Officer at Aktis Oncology. "With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies. This substantial clinical progress is a testament to our ability to execute rapidly with quality across multiple clinical trials and positions Aktis for a data-rich 2027."

Third quarter 2026 and recent business highlights

AKY-1189

AKY-1189 is a novel, clinical-stage miniprotein radioconjugate designed to selectively deliver actinium-225 (225Ac) to tumors expressing Nectin-4, a clinically and commercially validated target expressed in several tumor types, including locally advanced or metastatic urothelial cancer (mUC) and breast cancer.

Dose escalation is ongoing in the Phase 1b NECTINIUM-2 trial evaluating AKY-1189 in patients with locally advanced or mUC and other Nectin-4 expressing solid tumors.
Aktis initiated backfill at the 6 MBq dose level to further characterize safety and preliminary antitumor activity in up to 30 patients. This is the first of up to two dose levels planned to be selected for backfill.
AKY-2519

AKY-2519 is a novel, clinical-stage miniprotein radioconjugate designed to selectively deliver 225Ac to tumors expressing B7-H3, a clinically validated target expressed in prostate, lung, and other solid tumors.

Aktis initiated the Phase 1b BActinium-2 trial evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing solid tumors.
Dose escalation is ongoing in the Phase 1b BActinium-1 trial evaluating AKY-2519 in patients with metastatic castration-resistant prostate cancer (mCRPC), including PLUVICTO-naïve and PLUVICTO-experienced patients.
In the Phase 1b BActinium-1 trial, Aktis initiated backfill at the 9 MBq dose level for both the PLUVICTO-naïve and PLUVICTO-experienced cohorts to further characterize safety and preliminary antitumor activity in up to 30 patients per cohort. This is the first of up to two planned dose levels that will be backfilled in each of the mCRPC patient populations.
Dr. Roden added, "With our robust end-to-end supply chain supported by multiple contract manufacturing organizations and isotope suppliers, we are successfully delivering clinical supply for our clinical trials nationally. In the quarter, we operationalized our in-house GMP facility at 17 Drydock in Boston, where we expect to begin supplying drug product for our clinical trials in the first half of 2027, further expanding manufacturing capacity for clinical supply. The 17 Drydock facility progresses our strategy to build capabilities to support potential Phase 3 trials and commercial product supply in a capital-efficient manner."

Manufacturing

Aktis began manufacturing drug product in its in-house GMP facility, as part of the Company’s hybrid sourcing manufacturing strategy. Aktis intends to amend the INDs for AKY-2519 and AKY-1189 to include the in-house facility as a manufacturer of clinical supply for its ongoing clinical trials.
Anticipated milestones for the next 12 months

AKY-1189: Expect preliminary data from the ongoing Phase 1b NECTINIUM-2 trial in the first quarter of 2027.
AKY-2519: Expect preliminary data from the ongoing Phase 1b BActinium-1 trial in 2027.
Early pipeline: Two programs tracking toward development candidate nomination and commencement of IND-enabling activities in the first quarter of 2027.
Corporate: Expect to expand drug supply to include our in-house GMP facility to support ongoing clinical trials in the first half of 2027.
Third quarter 2026 financial results

Cash position: Cash, cash equivalents, and marketable securities were $492.9 million as of September 30, 2026, compared with $226.8 million as of December 31, 2025. The increase in cash, cash equivalents, and marketable securities reflects net proceeds from the Company’s initial public offering in January 2026, primarily offset by cash used in operations. The Company’s cash, cash equivalents, and marketable securities as of September 30, 2026, are expected to fund the Company’s operating plan into 2029.
Collaboration revenue: Collaboration revenue was $3.9 million for the quarter ended September 30, 2026, compared with $1.6 million for the comparable prior-year period. The increase of $2.3 million was attributable to continued advancement of the Company’s research collaboration with Eli Lilly and Company, with revenue recognized over time using the cost incurred input method.
R&D expenses: Research and development expenses were $32.1 million for the quarter ended September 30, 2026, compared with $16.5 million for the comparable prior-year period. The increase of $15.6 million was primarily driven by the advancement of clinical trials for AKY-1189 and AKY-2519 and increased headcount primarily in clinical development and manufacturing to support the advancement of the clinical pipeline.
G&A expenses: General and administrative expenses were $6.5 million for the quarter ended September 30, 2026, compared with $3.3 million for the comparable prior-year period. The increase of $3.2 million was primarily due to increased headcount to support company growth and increased activities associated with operating as a public company.
Net loss: Net loss was $29.9 million for the quarter ended September 30, 2026, compared with $15.5 million for the comparable prior-year period. The increase of $14.4 million was primarily driven by higher operating expenses, partially offset by increased collaboration revenue recognized and interest income, net.
PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is a registered trademark of Novartis Pharmaceuticals Corporation.

About NECTINIUM-2
The Phase 1b multicenter, open-label clinical trial is evaluating AKY-1189 in patients with locally advanced or mUC, breast cancer and other Nectin-4 expressing tumors. The trial will explore up to 5 dose levels in the dose escalation. Per protocol, Aktis has the ability to expand enrollment in backfill cohorts at selected dose levels and tumor types to generate additional clinical data while dose escalation continues. The trial is being conducted in the U.S. Additional information about the trial is available at clinicaltrials.gov using the identifier NCT07020117.

About BActinium-1
The Phase 1b multicenter, open-label clinical trial is evaluating AKY-2519 in patients with mCRPC, including PLUVICTO-naïve and PLUVICTO-experienced cohorts. The study will explore up to 3 dose levels in the dose escalation. Per protocol, Aktis has the ability to expand enrollment in backfill cohorts at selected dose levels to generate additional clinical data while dose escalation continues. The trial is being conducted in the U.S. Additional information about the trial is available at clinicaltrials.gov using the identifier NCT07581184.

About BActinium-2
The Phase 1b multicenter, open-label trial is evaluating AKY-2519 in patients with NSCLC and other B7-H3 expressing solid tumors. The study will explore up to 3 dose levels in the dose escalation. Per protocol, Aktis has the ability to expand enrollment at selected dose levels and tumor types to generate additional clinical data while dose escalation continues. The trial is being conducted in the U.S. Additional information about the trial is available at clinicaltrials.gov using the identifier NCT07887971.

About Aktis’ miniprotein radioconjugate platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anticancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end clinical supply chain built for resiliency and scalability, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

(Press release, Aktis Oncology, NOV 12, 2026, View Source [SID1234674700])

New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

On November 12, 2026 Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, reported their partner Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The submission was made under the FDA’s Real-Time Oncology Review (RTOR) program, which allows sponsors to submit clinical data in advance of the complete application to facilitate earlier review of efficacy and safety results. The completed application will undergo the standard review period with the FDA, and, if accepted, a Prescription Drug User Fee Act (PDUFA) target action date will be assigned.

The NDA is based on the Phase 3 REZILIENT3 trial, which met its primary endpoint at an interim analysis, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival (PFS) for zipalertinib plus chemotherapy versus chemotherapy alone. These results were presented in a Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Cullinan Therapeutics is eligible to receive $30 million and $100 million in milestone payments upon second-line and first-line U.S. regulatory approvals, respectively.

About Zipalertinib

Zipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib is investigational and has not been approved by any health authority.

Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.

About EGFR Exon 20 Insertion Mutations

NSCLC is a common form of lung cancer and up to 4% of all cases globally have EGFR ex20ins.1 In the United States, approximately 16% of patients with NSCLC harbor EGFR mutations,1 with insertions at exon 20 accounting for up to 12% of these mutations.

(Press release, Cullinan Oncology, NOV 12, 2026, View Source [SID1234674717])

Ascendis Pharma Reports Third Quarter 2026 Financial Results

On November 12, 2026 Ascendis Pharma A/S (Nasdaq: ASND) reported financial results for the third quarter ended September 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"By always putting patients first, Ascendis has delivered three consecutive approved rare endocrine therapies that are the foundation of our transformation into a leading global biopharmaceutical company," said Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma. "With many label expansion programs, new country launches, and the capabilities to reach patients worldwide and develop new products efficiently, we are well positioned to deliver durable long-term growth."

Select Highlights & Anticipated Milestones

•
YORVIPATH

(palopegteriparatide, developed as TransCon PTH)

•
YORVIPATH revenue for the third quarter of 2026 totaled €291 million (+103% Y/Y).

•
In the U.S., new patient demand was consistent with prior quarters. Outside the U.S., new patient demand accelerated through new commercial launches. YORVIPATH is now available commercially or through named patient programs in more than 40 countries.

•
Presented data from pooled analysis of Phase 2 PaTH Forward and Phase 3 PaTHway trials at ASN 2026 demonstrating sustained, clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon PTH for up to five years.

•
Results from the Phase 3 PaTHway China and PaTHway Japan trials evaluating TransCon PTH in adults with hypoparathyroidism demonstrated efficacy and safety findings consistent with those reported in the pivotal Phase 3 PaTHway Trial, reinforcing the consistency of results across geographies and ethnicities.

•
SKYTROFA

(lonapegsomatropin, developed as TransCon hGH)

•
SKYTROFA revenue for the third quarter of 2026 totaled €59 million.

•
Ongoing Phase 3 HighLiGHts basket trial across a range of established growth hormone indications: idiopathic short stature (ISS), SHOX deficiency, Turner syndrome, and small for gestational age (SGA). Completion of enrollment anticipated in the first half of 2027.

•
YUVIWEL

(navepegritide, developed as TransCon CNP)

•
YUVIWEL revenue for the third quarter of 2026 totaled €16 million.

•
In the U.S., approximately 340 unique YUVIWEL patient enrollments by nearly 150 prescribing healthcare providers, with more than 80% of enrollments approved for reimbursement through October 31, 2026.

•
In the EU, received positive CHMP and COMP opinions recommending marketing authorization as a treatment of achondroplasia in children and maintenance of orphan medicinal product designation, respectively, for once-weekly TransCon CNP. Final EC decision expected during the Q4 2026 with first EU launch planned in Germany in Q1 2027.

•
In select international markets, YUVIWEL is being made available through early access programs, and Ascendis expects to recognize revenue from multiple countries outside of the U.S. and EU in the coming quarters.

•
Presented infant sentinel cohort Week 52 data from the reACHin Trial at ESPE 2026, showing that treatment with once-weekly TransCon CNP stabilized or improved foramen magnum stenosis (a skull bone narrowing that can lead to brain stem and spinal cord compression), as well as linear growth benefits, in infants with achondroplasia aged 0 to <2 years. Pivotal data expected Q3 2027.

•
Expect to enroll first patients in Phase 3 trial evaluating TransCon CNP monotherapy in children with hypochondroplasia in Q4 2026. Expect to initiate a Phase 2 trial in adults with achondroplasia in Q4 2026.

•
TransCon CNP + TransCon hGH Combination Therapy

(navepegritide plus lonapegsomatropin)

•
Following presentation of additional Week 78 data from the Phase 2 COACH Trial at ASBMR 2026 showing durable increase in healthy, proportional growth in children with achondroplasia, 100% of the 21 enrolled children remain on therapy to date.

•
Initiated Phase 3 cAtCH Trial in children with achondroplasia; expect to complete enrollment in Q2 2027.

Key Financial Highlights

•
Total product revenue for the third quarter of 2026 increased to €366 million, reflecting year-over-year growth of +89%.

•
Total revenue for the third quarter of 2026 was €370 million.

•
Operating profit for the third quarter of 2026 totaled €125 million, reflecting a margin of 34%. On a non-IFRS basis, operating profit was €156 million*, reflecting a margin of 42%*.

•
Net profit for the third quarter of 2026 totaled €74 million, or €1.08 per diluted share. On a non-IFRS basis, net profit was €117 million*, or €1.71 per diluted share*.

•
Cash flow from operating activities was €189 million for the third quarter of 2026; expect full year 2026 cash flow from operating activities of at least €600 million.

•
As of September 30, 2026, cash and cash equivalents totaled €964 million, compared to cash and cash equivalents of €616 million as of December 31, 2025.

•
Through September 30, 2026, repurchased 794,304 Ascendis ordinary shares for total consideration of $186 million.

•
Year to date through November 11, 2026, repurchased 1,998,999 Ascendis ordinary shares for total consideration of $459 million.

*
See "Non-IFRS Financial Measures" below for definitions of these non-IFRS measures and a reconciliation to the most directly comparable IFRS measures.

Third Quarter 2026 Financial Results

Total revenue for the third quarter of 2026 was €370 million, compared to €214 million during the same period in 2025. The year-over-year increase in revenue was primarily attributable to the continued growth of YORVIPATH global sales.

Total Revenue
(In EUR’000s) Three Months Ended
September 30, Nine Months Ended
September 30,
2026 2025 2026 2025
Revenue


Commercial products

365,690 193,790 921,452 443,480
Other revenue


Milestones

—  12,922 17,046 12,922
Licenses, services and clinical supply

3,967 6,922 17,045 16,230

Total revenue

369,657 213,634 955,543 472,632

Revenue from Commercial Products
(In EUR’000s) Three Months Ended
September 30, Nine Months Ended
September 30,

2026 2025 2026 2025
Revenue from commercial products


YORVIPATH

290,626 143,089 739,634 290,735
SKYTROFA

59,424 50,701 158,595 152,745
YUVIWEL

15,640 —  23,223 — 

Total revenue from commercial products

365,690 193,790 921,452 443,480

Research and development expenses for the third quarter of 2026 were €70 million, compared to €67 million during the same period in 2025. The increase was due to increased clinical trial activities within the Endocrinology Rare Disease pipeline, partially offset by reduced clinical trial activities within Oncology.

Selling, general, and administrative expenses for the third quarter of 2026 were €147 million, compared to €113 million during the same period in 2025. The increase was primarily due to the continued commercial expansion, including global launch activities.

Total operating expenses for the third quarter of 2026 were €217 million, compared to €180 million during the same period in 2025.

Operating profit for the third quarter of 2026 was €125 million, reflecting a margin of 34%, compared to €11 million, reflecting a margin of 5% during the same period in 2025. The increase was primarily driven by higher revenue from the continued growth of YORVIPATH global sales, partially offset by higher operating expenses associated with global commercial expansion.

Net finance expenses for the third quarter of 2026 were €4 million, compared to €61 million in the same period in 2025. The change was primarily driven by non-cash items.

Net profit for the third quarter of 2026 was €74 million, or €1.13 per basic share and €1.08 per diluted share, compared to a net loss of €61 million, or €1.00 per basic and diluted share, for the same period in 2025.

Cash flows from operating activities for the nine months ended September 30, 2026, were €463 million compared to €20 million used in operating activities during the same period in 2025. The improvement was primarily attributable to commercial revenue growth and net proceeds from the sale of the PRV of €158 million (net of transaction costs), partially offset by less favorable changes in working capital of approximately €15 million and higher interest and income taxes paid.

As of September 30, 2026, Ascendis Pharma had 66,400,738 ordinary shares outstanding, of which 805,528 were held as treasury shares.

For the third quarter of 2026, non-IFRS operating profit was €156 million*, compared to a non-IFRS operating profit of €42 million* for the same period in 2025.

For the third quarter of 2026, non-IFRS net profit was €117 million*, or €1.71 earnings per diluted share*, compared to a non-IFRS net profit of €24 million*, or €0.40 earnings per diluted share*, for the same period in 2025.

Conference Call and Webcast Information

Ascendis Pharma will host a conference call and webcast today at 8:00 a.m. Eastern Time (ET) to discuss its third quarter 2026 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at View Source A replay of the webcast will be available in this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.

(Press release, Ascendis Pharma, NOV 12, 2026, View Source [SID1234674666])

Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov

On November 12, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported an expanded strategic advisory engagement with Dr. Artem (Art) Cherkasov, PhD, an existing member of the Company’s Scientific Advisory Board (SAB).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Cherkasov, an internationally recognized pioneer in computational drug discovery, artificial intelligence and precision cancer therapeutics, will continue to serve on Rakovina’s Scientific Advisory Board while taking on a more active role as Advisor AI Drug Discovery supporting the Company’s evaluation of new AI technologies, advancement of its discovery programs and pursuit of strategic partnerships.

Dr. Cherkasov’s expanded role fits closely with Rakovina’s AI strategy, which has three elements: strengthening the Company’s relationships with leading AI drug-discovery platforms, including securing exclusivity in its DNA-damage response (DDR) field; using multiple AI platforms, each specialized for different aspects of biochemistry and drug development, rather than relying on a single tool; and considering strategic alternatives, including mergers and acquisitions, that could add technologies, programs or scale.

Rakovina has been executing this strategy. On November 10, 2026, the Company announced an exclusive, worldwide and perpetual licence for DDR oncology drug discovery to the Artemis.AI platform, which incorporates Dr. Cherkasov’s Deep Docking technology, from Artemis Therapeutics Inc. ("Artemis"), where Dr. Cherkasov is a co-founder and Chief Technology Officer. On October 14, 2026, Rakovina announced that it had secured exclusivity over the optimized target product profile for its kt-5000 ATR inhibitor program from Variational AI Inc. ("Variational AI"), and on October [22], 2026, it reported that the kt-5000AI program, designed using Variational AI’s Enki generative AI platform, is advancing toward development candidate selection. On October 1, 2026, Rakovina announced a collaboration with Boston-based Celvion Therapeutics ("Celvion") to apply Celvion’s EMphora AI platform to real-world clinical data for its ATR inhibitor program, and on October 28, 2026, the companies reported the results of their first analysis. These news releases are available on the Company’s website at www.rakovinatherapeutics.com and on SEDAR+ at www.sedarplus.ca.

"Our strategy is to build the strongest position we can in AI-enabled DDR drug discovery: exclusive access to the best platforms in our field, the flexibility to apply the right specialized AI to each problem, and openness to strategic transactions that can accelerate our growth," said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. "Art has been using AI to accelerate drug discovery for more than 20 years and has an internationally recognized track record, and few people are better placed to judge which AI technologies will deliver results in the lab. His expanded involvement will help us evaluate emerging technologies, deepen our AI partnerships and assess corporate development opportunities as we execute our growth strategy."

A World-class Scientific Leader with a Track Record of Commercial Innovation

Dr. Cherkasov is a Professor in the Department of Urologic Sciences at the University of British Columbia (UBC), a Tier 1 Canada Research Chair in Precision Cancer Drug Design and a Senior Scientist at the Vancouver Prostate Centre.

Over the course of his distinguished career, he has established an exceptional international reputation for applying computational science, machine learning and artificial intelligence to accelerate pharmaceutical discovery and therapeutic innovation.

His accomplishments include:

Pioneer of Deep Docking: Developed the groundbreaking AI-enabled drug discovery platform capable of screening billions of molecular structures against specific biological targets, dramatically accelerating the identification of potential drug candidates.

Landmark Roche / UBC Pharmaceutical Agreement: His research and computational drug discovery work contributed to a landmark licensing and commercialization agreement between UBC and Roche involving a potential treatment for advanced prostate cancer. Announced in 2015, the agreement included potential milestone payments of up to US$141.7 million, plus royalties, representing one of the most significant pharmaceutical commercialization agreements in UBC’s history.

COVID-19 AI Research Breakthrough: During the pandemic, Dr. Cherkasov led an interdisciplinary research initiative applying Deep Docking to identify potential inhibitors of SARS-CoV-2. Working with NVIDIA, Dell Technologies and UBC Advanced Research Computing, his team computationally screened approximately 40 billion molecular structures in just 19 days, identifying promising candidates for further investigation.

International AI Drug Discovery Recognition: His Deep Docking technology achieved first-place results in two international CACHE drug discovery challenges, including initiatives focused on Parkinson’s disease and COVID-19.

Extensive Intellectual Property and Research Portfolio: Dr. Cherkasov has co-authored more than 200 peer-reviewed scientific publications, contributed to more than 80 patent filings and helped advance eight drug candidates that have been licensed to pharmaceutical companies and commercial partners.

Significant Research Leadership: His work at UBC and the Vancouver Prostate Centre has attracted more than CAD $80 million in research funding, supporting advances in computational drug discovery, molecular modelling, cheminformatics and precision oncology.

Dr. Cherkasov’s career exemplifies the potential of AI to fundamentally transform traditional drug discovery by enabling researchers to explore vastly larger chemical spaces, prioritize promising compounds and accelerate the transition from computational predictions to experimental validation.

"AI and computational approaches are fundamentally changing how we discover and develop new therapeutics, creating significant opportunities to accelerate innovation," said Dr. Art Cherkasov. "Realizing this potential requires the integration of scientific expertise, advanced technologies and strategic collaboration. I am pleased to expand my involvement with Rakovina and look forward to working with the team to strengthen its discovery capabilities, explore new opportunities and help shape the Company’s next phase of growth."

The Company believes that realizing the full potential of AI-driven drug discovery requires more than computational capabilities alone. Rakovina combines expertise in AI-enabled drug design with established wet-laboratory research capabilities and deep experience in oncology drug development, enabling the Company to advance promising AI-generated compounds through experimental validation, biological testing and further preclinical development. This integrated approach positions Rakovina to translate computational discoveries into tangible therapeutic opportunities.

"Art brings exceptional expertise in computational drug discovery that complements Rakovina’s strengths in cancer biology, experimental validation and preclinical drug development," said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. "The true potential of AI-driven drug discovery lies in our ability to translate computational predictions into compounds with demonstrated biological activity and therapeutic potential. By combining Art’s expertise with our established wet-laboratory capabilities and oncology research experience, we see significant opportunities to strengthen our discovery programs and accelerate the advancement of promising new cancer therapeutics."

Securities for Services Arrangement

In connection with his expanded role, the Company has entered into a consulting agreement with Dr. Cherkasov effective November 15, 2026, for a term of up to 24 months (the "Consulting Agreement"). Under the Consulting Agreement, Dr. Cherkasov will continue to serve on the Company’s Scientific Advisory Board and will provide advice on AI-enabled drug discovery and development and scientific and technical due diligence on new AI platforms. The services do not include investor relations, promotional or market-making activities.

Dr. Cherkasov will receive compensation of $160,000 per year, of which $100,000 is payable in cash in equal monthly instalments and $60,000 ($15,000 per quarter) is payable in common shares of the Company ("Shares") under a securities-for-services arrangement in accordance with section 6.2 of TSX Venture Exchange ("TSXV") Policy 4.4 – Security Based Compensation.

Shares will be issued quarterly in arrears, only after the services for the applicable quarter have been provided. The number of Shares for each quarter will be determined after the end of that quarter by dividing $20,000 by a deemed price per Share that will not be less than the Discounted Market Price (as defined in TSXV policies) on the date of determination. No warrants will be issued under the arrangement.

Dr. Cherkasov is Non-Arm’s Length Party of the Company. He is a co-founder, director and Chief Technology Officer of Artemis Therapeutics Inc., which is expected to receive Shares as consideration for the Artemis.AI licence announced on November 10, 2026. The arrangement will not result in the creation of a new Control Person. The issuance of Shares is subject to TSXV acceptance, and the Shares will be subject to a hold period of four months and one day from the date of issuance under applicable securities laws. The Company will issue a news release each quarter disclosing the number of Shares issued under the arrangement.

Joint Webinar

Rakovina Therapeutics will host a joint webinar with Artemis Therapeutics on November 18th at 11:30AM PCT (Vancouver time) to discuss the recently announced collaboration between the two companies. The webinar will feature Mr. Kim Oishi CEO of Rakovina, Mr. Frank Holler, CEO of Artemis and Dr. Artem Cherkasov, Co-Founder and CTO of Artemis.

(Press release, Rakovina Therapeutics, NOV 12, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-expands-strategic-engagement-with-renowned-ai-drug-discovery-pioneer-dr-artem-cherkasov [SID1234674683])